- Major pharmaceutical companies including Sanofi, Regeneron, Roche, Eli Lilly, Biogen, and Gilead are maintaining alliances and competing across key therapeutic areas like ophthalmology, immunology, and oncology.
- Collaboration agreements for oncology candidates were signed between several major pharmaceutical companies.
- A partnership involving Recursion Pharmaceuticals, Sanofi, Roche, Merck, and Relay Therapeutics diversifies pipelines across oncology and immunology, leveraging AI-driven platforms.
Lunit and Discovery Life Sciences Partner to Expand AI in Drug Discovery
What happened
Lunit, a provider of AI for cancer diagnostics, announced a collaboration with Discovery Life Sciences, a global leader in biospecimens. The partnership aims to expand the use of Lunit's AI-powered pathology platform, SCOPE, across biopharmaceutical research programs. Together, the companies will apply the AI platform within Discovery's tissue and biomarker analysis workflows for clients.
From manilatimes.net
Why it matters
The collaboration seeks to provide pharmaceutical and biotechnology companies with standardized, quantitative tissue insights. This support is intended to accelerate evidence generation throughout drug development and improve the reproducibility of tissue-based analysis.
Several major pharmaceutical companies are currently diversifying their pipelines across oncology and immunology by leveraging AI-driven platforms.
From manilatimes.net
Who's involved
- Yoojoo LimResearcher